Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
Kan YonemoriKeiichi FujiwaraKosei HasegawaMayu YunokawaKimio UshijmaShiro SuzukiAyumi ShikamaShinichiro MinobeTomoka UsamiJae-Weon KimByoung Gie KimPeng-Hui WangTing-Chang ChangKeiko YamamotoShirong HanJodi-Ann MckenzieRobert J OrlowskiTakuma MiuraVicky MakkerYong Man KimPublished in: Journal of gynecologic oncology (2024)
ClinicalTrials.gov Identifier: NCT03517449.